AmBisome

AmBisome is indicated for the following:

• empirical therapy for presumed fungal infection in febrile, neutropenic patients;

• treatment of Cryptococcal Meningitis in HIV-infected patients;

• treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate;
• treatment of visceral leishmaniasis; in immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites.